CAS: 1403-66-3; Gentamicin

该化合物是一种主要用于治疗各种细菌感染,特别是由克己细菌引起的细菌感染的微粒素,其来源是微子素,以其广泛的抗微生物活动著称; 基因蛋白素,抑制细菌蛋白合成,最终导致细胞死亡; 该物质通常通过注射或切除施用方式施用,因为胃肠道吸收不良; 其化学结构具有多种氨基化合物,促成其溶解于水和渗透细菌细胞膜的能力; 基因蛋白素经常用于临床环境,用于严重感染,包括影响呼吸道,尿道和血液的感染; 但是,由于潜在的肾脏毒性和食毒,监测其使用十分重要,因为这种作用可能长期接触或高剂量. 总的来说, 红蛋白素仍然是治疗严重细菌感染的关键工具,特别是在医院环境中.

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-2024197774-A1
    优先权日:2021-04-16
    标 题:Synthesis of Antimicrobial PVP-coated Bismuth Nanoparticles
    发明人:LOPEZ-RIBOT JOSE; VAZQUEZ-MUNOZ ROBERTO
    权利人:UNIV TEXAS
    摘要:Described herein is a facile, fast, and economical method for the synthesis of BAL-mediated PVP-BiNPs, using basic laboratory instruments and reagents readily available in most laboratories.

    专利号:US-8557979-B2
    优先权日:2004-06-10
    标题 :Carbapenem antibacterials with gram-negative activity and processes for their preparation
    发明人:CHOI WOO-BAEG; KOWALIK EWA
    权利人:CHOI WOO-BAEG; KOWALIK EWA; FOB SYNTHESIS INC
    摘要:The present invention provides β-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment. The present invention is also in the field of synthetic organic chemistry and is specifically provides an improved method of synthesis of β-methyl carbapenems which are useful as antibacterial agents.

    专利号:US-10933051-B2
    优先权日:2017-06-09
    标 题 :Carbapenem compounds and compositions for the treatment of bacterial infections
    发明人:CHOI WOO-BAEG; TOMIOKA TAKASHI; JOO HYUNG-YEUL; TRUONG PHONG; MIN BRIAN
    权利人:FOB SYNTHESIS INC
    摘要:The present invention provides carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections, including drug resistant or multiple-drug resistant bacterial infections, and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment.

    专利号:US-2008051323-A1
    优先权日:2004-08-21
    标 题 :Chloroquine drug compositions and methods for their synthesis
    发明人:KOSAK KENNETH M
    权利人:KOSAK KENNETH M
    摘要:This invention discloses compositions of chloroquine-coupled active agents, including methods for their preparation. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these compositions is to provide a controlled amount of chloroquine at the same site where the active agent is delivered, thereby reducing the overall dosage needed. n The compositions comprise a chloroquine substance coupled to an active agent directly or through a variety of pharmaceutical carrier substances. The carrier substances include polysaccharides, synthetic polymers, proteins, micelles and other substances for carrying and releasing the chloroquine compositions in the body for therapeutic effect. The compositions can also include a biocleavable linkage for carrying and releasing active agents for therapeutic or other medical uses. The invention also discloses carrier compositions that are coupled to targeting molecules for targeting the delivery of chloroquine substances and active agents to their site of action.

    专利号:US-2007060499-A1
    优先权日:2005-09-15
    标 题 :Chloroquine combination drugs and methods for their synthesis
    发明人:KOSAK KENNETH M
    权利人:KOSAK KENNETH M
    摘要:This invention discloses compositions of chloroquine-coupled active agents, including methods for their preparation. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these compositions is to provide a controlled amount of chloroquine at the same site where the active agent is delivered, thereby reducing the overall dosage needed. The compositions comprise a chloroquine substance coupled to an active agent directly or through a variety of pharmaceutical carrier substances. The carrier substances include polysaccharides, synthetic polymers, proteins, micelles and other substances for carrying and releasing the chloroquine compositions in the body for therapeutic effect. The compositions can also include a biocleavable linkage for carrying and releasing active agents for therapeutic or other medical uses. The invention also discloses carrier compositions that are coupled to targeting molecules for targeting the delivery of chloroquine substances and active agents to their site of action.

    专利号:US-9937151-B2
    优先权日:2010-06-18
    标题 :Carbapenem antibacterials with gram-negative activity
    发明人:CHOI WOO-BAEG; GRUSZECKA-KOWALIK EWA; JOO HYUNG-YEUL; LIU SHUANGPEI; MAO SHULI; LI YONGFENG; KIM DEOG-IL
    权利人:FOB SYNTHESIS INC
    摘要:The present invention provides β-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment.
    杭州维华生物技术有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.viwachina.com
    电话: 86-0571-56003631 56003555👤
    📞杭州维华生物技术有限公司 ⚠️参考联系方式

    销售电话:86-0571-56003631 56003555
    邮箱:sales@viwachina.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Burton AJ, Giguère S, Arnold RD. Pharmacokinetics, pulmonary disposition and tolerability of liposomal gentamicin and free gentamicin in foals. Equine Vet J. 2015 Jul;47(4):467-72. doi: 10.1111/evj.12309. Epub 2014 Aug 18. doi: 10.1111/j.1532-950X.2014.12115.x. Epub 2014 Jan 10. doi: 10.1111/jvim.13626. Epub 2015 Oct 1.
    4: Johnston C, Hilmer SN, McLachlan AJ, Matthews ST, Carroll PR, Kirkpatrick CM. The impact of frailty on pharmacokinetics in older people: using gentamicin population pharmacokinetic modeling to investigate changes in renal drug clearance by glomerular filtration. Eur J Clin Pharmacol. 2014 May;70(5):549-55. doi: 10.1007/s00228-014-1652-7. Epub 2014 Feb 14. doi: 10.4067/S0716-10182016000100001. Spanish. doi: 10.1128/AAC.00378-13. Epub 2013 May 6.
    7: Veinstein A, Venisse N, Badin J, Pinsard M, Robert R, Dupuis A. Gentamicin in hemodialyzed critical care patients: early dialysis after administration of a high dose should be considered. Antimicrob Agents Chemother. 2013 Feb;57(2):977-82. doi: 10.1128/AAC.01762-12. Epub 2012 Dec 10.

    合成参考文献


    摘要:Japanese Journal of Antibiotics., 30(386), 1977 []
    摘要:Antibiotiki., 21(532), 1976 []
    摘要:Medical Economics Company; Clinical Laboratory Reference, 7th ed, June 1980
    摘要:Lyman WJ et al; Handbook of Chemical Property Estimation Methods. Washington, DC: Amer Chem Soc pp. 7-4, 7-5, 8-12 (1990)
    摘要:NIH/NLM; ClinicalTrials.Gov. Available from, as of February 1, 2017: https://clinicaltrials.gov/ct2/results term=GENTAMYCIN&Search=Search
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知